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Comprehensive Analysis of Pulmonary Function Test (PFT)
Changes After Stereotactic Body Radiotherapy (SBRT) for
Stage I Lung Cancer in Medically Inoperable Patients
Kevin L. Stephans, MD,* Toufik Djemil, PhD,* Chandana A. Reddy, MS,* Stephen M. Gajdos, MS,*
Mathew Kolar, MS,* Michael Machuzak, MD,† Peter Mazzone, MD,†
and Gregory M. M. Videtic, MD*
Background: To assess for variables predicting pulmonary function
test (PFT) changes after stereotactic body radiotherapy (SBRT) for
medically inoperable stage I lung cancer.
Methods: We reviewed 92 consecutive patients undergoing SBRT
for stage I lung cancer between February 2004 and August 2007. A
total of 102 lesions were treated using prescriptions of 20 Gy  3
(n  40), 10 Gy  5 (n  56), and 5 Gy  10 (n  6). Institutional
practice was 10 Gy 5 before March 1, 2006 before changing to 20
Gy  3 to conform to RTOG 0236 unless otherwise dictated
clinically.
Results: Median pretreatment forced expiratory volume at 1 second
(FEV1) was 1.21 liter (50% of predicted) and median diffusion
capacity to carbon monoxide (DLCO) was 56.5. There was no
significant overall change in PFT’s after SBRT. Individual patients
experienced both substantial improvements and declines (10% de-
clined at least 14% predicted FEV1% and 19% predicted DLCO).
The mean change in FEV1 was 0.05 liter (range, 0.98 to 1.29
liter; p  0.22) representing 1.88% predicted baseline FEV1
(range, 33 to  43%; p  0.62). DLCO declined 2.59% of
predicted (range, 37 to 33%; p  0.27). Conformality index, V5
and V10 were associated with individual patient changes in FEV1%
(p  0.033, p  0.0036, p  0.025, respectively), however,
correlations were small and overall treatment dose did not predict
for changes (p  0.95). There was no significant difference in FEV1
(p  0.55) or FEV1% (p  0.37) changes for central versus
peripheral locations. No factors predicted for individual changes in
DLCO. Patients with FEV1% below the median of the study popu-
lation had significantly longer overall survival (p  0.0065). Al-
though patients dying of cardiac disease died earlier than those
dying of other causes, FEV1% below median was not associated
with a lower risk of dying of cardiac disease or with lower Charlson
comorbidity index.
Conclusions: (1) SBRT was well tolerated and PFT changes were
minimal. (2) Central lesions were safely treated with 50 Gy.
Key Words: Stereotactic body radiation, Stage I lung cancer,
Medically inoperable, Pulmonary function.
(J Thorac Oncol. 2009;4: 838–844)
Surgical resection is the standard of care for stage I non-small cell lung cancer (NSCLC).1,2 A significant number
(30–60%) of stage I patients, however, are medically inop-
erable secondary to comorbidities3,4 the most common of
which is chronic obstructive pulmonary disease.5 Conven-
tional radiotherapy of 60 to 70 Gy offered to inoperable
patients results in high local failure rates and 5-year overall
survivals of 15 to 30%.6 The literature, however, suggests
that there exists a radiotherapy dose-response effect in
NSCLC.6,7
Stereotactic body radiotherapy (SBRT) offers a novel
means of safely delivering very high-radiation doses to stage
I NSCLC. Onishi et al.8 reported a 5-year local control and
overall survival rate of 84% and 54%, respectively, following
SBRT to a median biologic equivalent dose of 100 Gy.
Several series have demonstrated similar results for SBRT
regimens ranging from 48 to 60 Gy in 3 to 10 fractions.4,9–18
The potential benefits of SBRT for cancer control in a
vulnerable population should not be mitigated by toxicity,
especially with reference to pulmonary function. Although
most studies describe SBRT as well tolerated in these pa-
tients, there are reports of exacerbations of dyspnea,5 radia-
tion pneumonitis,19 or airway obstruction14 after treatment. In
the preliminary toxicity analysis of RTOG 0236, a recently
completed phase II study, one episode of grade 4 (2%) and 7
episodes of grade 3 (13%) pulmonary/upper respiratory
events were reported, many of which were decreases in
pulmonary function test (PFT) values.20 Some studies on PFT
changes describe minimal or transient alterations with
SBRT.15,21–23 These contrasting reports prompted us to study
further the effects of SBRT treatment and dosimetry on
objective measures of pulmonary function in medically inop-
erable patients.
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METHODS
Patient and Tumor Characteristics
All data was collected within an institutional-review
board approved registry. Between February 2004 and August
2007, 92 patients with clinical AJCC T1A or T1B lung cancer
were treated with SBRT for 102 lesions (5 synchronous and
5 metachronous primaries). All patients were deemed medi-
cally inoperable by multidisciplinary evaluation. Evaluation
included history and physical examination, contrast-enhanced
computed tomography (CT) of the chest, [18F]fluorodeoxy-
glucose positron emission tomography, and PFTs including
forced expiratory volume at 1 second (FEV1) and diffusion
capacity to carbon monoxide (DLCO). Selection for SBRT
was not limited by pulmonary status or tumor location.
Charlson comorbidity index scores were retrospectively cal-
culated from initial patient history24 with no points assigned
for the lung cancer under treatment. Initial follow-up was 6 to
8 weeks after SBRT with same-day PFTs and chest CT.
Thereafter, routine follow-up was every 3 months with CT
imaging at each visit and PFTs twice yearly. Toxicity was
assessed according to the Common Terminology Criteria for
Adverse Events version 3.0.
Treatment Procedure
Patients were simulated supine in a vacuum bag restric-
tion system (BodyfixR, Elekta Inc, Stockholm, Sweden). An
abdominal compression device was applied to reduce respi-
ratory movement and adjusted under fluoroscopy. A 3-mm
slice thickness planning axial CT scan was taken during quiet
breathing, full inspiration and full expiration. Treatment plans
were generated by BrainScan 5.31 (BrainLAB, Feldkirchen,
Germany) planning software referenced to the free-breathing
study. Patients were treated on a Novalis (BrainLAB, Feld-
kirchen, Germany) machine using orthogonal films and the
ExacTrac (BrainLAB, Feldkirchen, Germany) stereotactic
body system for positioning.
Gross tumor volume was delineated on each respiratory
study using “lung window” setting. Critical structures includ-
ing lungs, spinal cord, heart, brachial plexus, and esophagus
were outlined and limited according to accepted standards.
Lesions before March 2006 (n  46) were preferentially
treated to 50 Gy in 5 fractions, according to the principles of
Uematsu et al.16 In March 2006, we adopted ROTG 0236
planning criteria25 and a prescription of 60 Gy in 3 fractions.
Patients with central tumors, defined as within 2 cm of the
tracheobronchial tree per RTOG 0236, were treated to 50 Gy
in 5 fractions. Six patients with large planning target volumes
directly adjacent to critical structures were treated to 50 Gy in
10 fractions. Measures of dose uniformity included confor-
mality index defined as the maximum dose at any point
divided by the prescription dose and heterogeneity index
defined as the prescription isodose volume divided by the
tumor volume.
Statistical Analysis
The primary end point was any change in pulmonary
function measured from the time of treatment to the latest
available measurement at least 6 months post SBRT. PFT
changes were assessed with a paired sign test. Kendall’s rank
correlations, Mann-Whitney tests, and Kruskal-Wallis tests were
used to correlate patient and treatment related variables to
individual PFT changes. Mann-Whitney tests were used to
compare time to cardiac compared with other causes of death,
FEV1% by cause of death (cardiac versus all others), as well as
correlation of Charlson scores by the FEV1% median value.
Fisher exact test was used to compare cause of death to FEV1%
above or below median. Overall survival by FEV1% and DLCO
cutoffs was analyzed using Kaplan-Meier curves, and the log-
rank test was used to determine whether a statistically significant
difference was present among patient groups. Univariate and
multivariate analysis for overall survival were performed using
Cox Proportional Hazards regression. Statistical analyses were
performed using StatView 5.0 (SAS Institute, Cary, NC) and
p value 0.05 was considered statistically significant.
RESULTS
Characteristics of the 92 patients are shown in Table 1.
The most common reason for medical inoperability was
predicted postresection FEV1 less than 0.8 liter. Reasons for
inoperability and prevalence of select comorbidities are listed
in Table 2. Median follow-up was 18.4 months (range,
1.7–48 months) and median time to most recent PFTs was
10.4 months. Local control was 98% and no patient died of
isolated local failure. Median overall survival was 18 months
(range, 1.9–48 months). Median pretreatment FEV1 was 1.21
liter (range, 0.41–2.72 liter) and median % predicted FEV1
(FEV1%) was 50% (range, 15–138%). Median DLCO was
56.5% of predicted (range, 14–143%) with higher values
seen in patients with cardiac and vascular comorbidities.
Dosimetric description of SBRT treatments is provided in
TABLE 1. Patient Characteristics (n  92)
Characteristic Median (Range)
Age 74 yr (44–89)
KPS 80 (40–90)
Gender (female) 54%
Stage (n  102)
T1 73
T2 29
Histology (n  102)
Squamous 16
Adenocarcinoma 33
Poorly diff/other 17
No biopsy 36
Involved lobe (n  102)
Upper:Middle:Lower 63:15:26
Location (Peripheral:Central) 92:10
History of smoking 92%
Active smoking (yes) 23%
FEV1 (liter) 1.21  0.52
FEV1 (as % of predicted) 50  24.5%
DLCO (as % of predicted) 56.5  22.6%
FEV1, forced expiratory volume at 1 second; DLCO, diffusion capacity to carbon
monoxide.
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Table 3. A total of 68 patients had both baseline and 6
month post treatment FEV1 data while 41 patients had both
baseline and 6 month posttreatment DLCO data. There was
no significant change in any measure of pulmonary function
following SBRT. The mean change in FEV1 was 0.05 liter
(range, 0.98 to 1.29 liter, SD 0.37 liter; p  0.22)
representing1.88% predicted baseline FEV1 (range,33 to
 43%, SD 12%; p  0.62). DLCO declined 2.59%
of predicted (range, 37 to 33%, SD 15%; p  0.27).
Although the mean change in pulmonary function was
not significant for the group as a whole, 10% of patients
experienced an absolute FEV1% decline of at least 14.8%
predicted while another 10% experienced an increase of at
least 12.7%. Additionally, 10% of patients experienced an
absolute DLCO decline of at least 19.4% of predicted while
10% experienced an increase of at least 18%. The distribution
of changes in FEV1% and DLCO are shown in Figures 1, 2.
There were no differences in patient or treatment character-
istics between the 20% of patients with largest increase in
FEV1% compared with 20% with largest decline in FEV1%.
Two patients experienced grade 2 radiation pneumonitis, both
resolved with oral steroids. There were no cases of grade 3
(requiring or increased supplemental oxygen) pneumonitis.
Given individual PFT variations we examined the ef-
fects of radiation dose and dose distribution upon pulmonary
function, as in Table 4. Increasing conformality index, V5
and V10 were correlated with greater declines in FEV1%
(p  0.033, p  0.0036, p  0.025, respectively), however,
had low Tau values (Tau  0.180, Tau  0.244, Tau 
0.188) suggesting that the magnitude of correlation was
small. No other variables were correlated with FEV1% de-
cline notably including total dose, age, involved lobe, or
central versus peripheral location. Specifically regarding tu-
mor location, the median change in FEV1 for all central
lesions was 0.06 liter or 3% predicted FEV1% (range,
18 to  16%) while the median change in FEV1 for
peripheral lesions was 0.08 liter or 3% predicted FEV1%
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FIGURE 1. Frequency Distribution of Change in forced ex-
piratory volume at 1 second (FEV1)%.
FIGURE 2. Frequency Distribution of Change in diffusion
capacity to carbon monoxide (DLCO).
TABLE 2. Patient Co-morbidities (n  92)
Number
Reason for inoperability
Pulmonary 62 (67%)
Cardiac 17 (18%)
Vascular 6 (7%)
Multiple (of above) 4 (4%)
Poor KPS 3 (3%)
Comorbid illnesses
COPDa 81 (87%)
Prior myocardial infarction 18 (19%)
Congestive heart failureb 24 (26%)
Prior symptomatic stroke 14 (15%)
Prior malignancy 42 (45%)
Charlson score24 3  2.4
a FEV1/FVC 0.7 and symptomatic.
b Framingham criteria.30
COPD, chronic obstructive pulmonary disease.
TABLE 3. SBRT Dosimetry (n  102)
Characteristic Median  SD
Prescription
20 Gy  3 40
10 Gy  5 56
5 Gy  10 6
GTV volume (ml) 7.9  14.2
PTV volume (ml) 34.5  32.0
Maximum PTV dimension (cm) 4.6  1.4
PTV coverage (%) 99.8  1.3%
Heterogeneity index 1.16  0.15
Conformality index 1.48  0.25
Total lung volume (ml) 3,708  1262
V5 (ml) (% of total lung volume) 572  326 (16%)
V20 (ml) (% of total lung volume) 148  130 (3.9%)
V30 (ml) (% of total lung volume) 85  75 (2.2%)
V50 (ml) (% of total lung volume) 35  33 (0.96%)
PTV, planning target volume; GTV, gross tumor volume.
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(range, 33 to 43%). This difference was not statistically
significant for central versus peripheral location for FEV1
(p  0.55) or FEV1% (p  0.37). Comparison of DLCO
changes was not done as only two patients with central
lesions had pre and post SBRT DLCO. No patient or treat-
ment related variable was predictive of DLCO changes (Ta-
ble 5), though age (p  0.085) and continued smoking (p 
0.095) approached significance.
To examine the tolerability of SBRT in patients with
varying degrees of lung function we divided patients into
quartiles based on baseline PFTs. Patients with the lowest
FEV1% values had better overall survival regardless of
whether patients were divided by the lowest quartile, below
the median (Figure 3), or below the 75th percentile (p 
0.041, p  0.0046, and p  0.020, respectively). When
patients were divided based on baseline DLCO there was no
survival difference for the lowest quartile, below the median
(Figure 4) or below the 75th percentile (p  0.55, p  0.44,
p  0.73, respectively).
To investigate potential factors influencing the survival
of patients with higher baseline FEV1%, we calculated the
mean survival by cause of death (Table 6). Survival was
significantly shorter for patients dying of cardiac disease
compared with other causes (median 9.2 versus 19.0 months,
p 0.028). All cardiac deaths occurred in patients with FEV1%
at or above the median. However, patients with FEV1% above
the median also died twice as often from noncardiac causes, and
the median FEV1% of patients dying of cardiac death was not
significantly higher than patients dying of other causes (65%
versus 58%, respectively, p  0.28).
Charlson comorbidity index correlated with overall
survival on univariate analysis (p  0.0032, hazard ratio
[HR]  1.31). Patients with FEV1% above the median,
however, did not have statistically higher Charlson scores and
the median for both groups was 3, p  0.58. A modified
Charlson score including additional points for modern cardiac
risk factors of known coronary artery disease, hypertension,
hyperlipidemia, and body mass index 30 was also tested,
but was not found to be a stronger predictor of survival (p 
0.0065, HR  1.27) than the standard Charlson score. Pa-
tients with FEV1% above median did not have statistically
higher modified Charlson scores than those below median
(p  0.23).
In addition, we analyzed the effects of age, stage (IA
versus IB), KPS, gender, active smoking, FEV1% (both as a
continuous variable and  median), and DLCO on overall
survival. Stage IB (p 0.0061, HR 2.83) and FEV1% (p
0.0059, HR  1.023 per % predicted and p  0.0063, HR 
3.40 for FEV1%  median) were correlated with overall
survival.
Two separate multivariate analyses were conducted
given that absolute FEV1% and FEV1%  median are de-
pendent upon each other. In the first, both FEV1% as a
continuous variable (p  0.012, HR  1.021 per %) and
stage (p  0.031, HR  2.51) significantly predicted for
survival whereas Charlson score approached significance
(p  0.066, HR 1.22). In the second, FEV1%  median
(p  0.0065, HR  3.44) and stage (p  0.044, HR  2.48)
significantly predicted for survival whereas Charlson score
did not (p  0.13, HR  1.18).
DISCUSSION
This study on the effects of SBRT on pulmonary
function in medically compromised patients found (1) no
TABLE 4. Factors Influencing FEV1% Changes (post-pre)/pre
Age 0.032 0.70
Active smoking — 0.53
Prescription dose — 0.95
Involved lobe — 0.90
Location (Peripheral vs. Central) — 0.35
Arcs vs. IMRT — 0.99
GTV volume (ml) 0.046 0.59
PTV volume (ml) 0.063 0.45
Maximum PTV dimension (cm) 0.054 0.53
Heterogeneity index 0.091 0.27
Conformality index 0.180 0.03
Total lung volume (ml) 0.199 0.017
V5 (ml) 0.244 0.0036
V10 ((ml) 0.188 0.025
V15 (ml) 0.157 0.06
V20 (ml) 0.139 0.10
V25 (ml) 0.137 0.10
V30 (ml) 0.142 0.09
V50 (ml) 0.129 0.12
%V20 (as % of lung volume) 0.048 0.57
IMRT, Intensity Modulated Radiation Therapy; PTV, planning target volume;
GTV, gross tumor volume.
TABLE 5. Factors Influencing DLCO Changes (post-pre)/pre
Variable Tau p
Age 0.187 0.085
Active smoking — 0.095
Prescription dose — 0.30
Involved lobe — 0.76
Location (Peripheral vs. Central) — 0.20
Arcs vs. IMRT 0.21
GTV volume (ml) 0.129 0.23
PTV volume (ml) 0.028 0.79
Maximum PTV dimension (cm) 0.108 0.32
Heterogeneity index 0.155 0.15
Conformality index 0.048 0.66
Total lung volume (ml) 0.119 0.27
V5 (ml) 0.023 0.83
V10 (ml) 0.033 0.76
V15 (ml) 0.136 0.21
V20 (ml) 0.161 0.14
V25 (ml) 0.173 0.11
V30 (ml) 0.160 0.11
V50 (ml) 0.168 0.12
%V20 (as % of lung volume) 0.157 0.15
IMRT, Intensity Modulated Radiation Therapy; PTV, planning target volume;
GTV, gross tumor volume.
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significant long-term change in FEV1, FEV1%, or DLCO
after treatment and (2) no grade 3 or higher clinical toxicities.
This is supported by other series: An Indiana University dose
escalation study in SBRT demonstrated an initially minimal
decline in PFTs followed by a return to baseline,15 while
patients treated on their phase II protocol demonstrated no
change in FEV1 with a small decline in DLCO of 1.11
mg/min/mm Hg/y.21 Ohashi described no change in FEV1
and an increase in DLCO in a small population of Japanese
patients.22 Two abstracts with a total of 48 patients reported
larger magnitude median declines in FEV1% and DLCO,
however, were not noted to be statistically significant.26,27
The Indiana series and ours are the largest reported with
details on PFT changes at this point and suggest minimal
changes which may be comparable to those expected by
aging. In addition we performed detailed analysis looking at
the relationship between morbidity and mortality patterns and
looked for associations with the PFT changes.
To investigate individual variations in PFTs we exam-
ined their correlation with patient, tumor, and dosimetric
parameters. Despite large variations in biologic equivalent
dose of the 3 treatment regimens in our population there was
no effect of dose on FEV1% (p  0.95) or DLCO (p  0.30)
suggesting that altering dose for patients with poor pulmo-
nary function is not necessary. In addition, there was no
difference between upper and lower lobe tumors or central
versus peripheral location. While frequent grade 3 pulmonary
FIGURE 3. Overall Survival by Baseline forced
expiratory volume at 1 second (FEV1)%.
FIGURE 4. Overall Survival by Baseline diffusion
capacity to carbon monoxide (DLCO).
TABLE 6. Overall Survival by Cause of Death
Cause of Death Median Survival (mo) % of Patients
Cardiac (n  8) 9.2 25.0
Pulmonary (n  4) 19.2 12.5
Lung CA (n  15) 15.8 46.9
Othera (n  3) 19.0 9.4
Unknown (n  2) 19.4 6.2
a GI bleed, cerebral hemorrhage and hip fracture complications.
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complications have been reported for central tumors treated
to 60 to 66 Gy,14 we treated central lesions to 50 Gy and
found no differences in PFT changes compared with periph-
eral lesions. Japanese investigators have also safely treated
central lesions to doses 60 Gy.8,16 We did find higher
conformality index, V5 and V10 were associated with larger
declines in FEV1%. Correlation scores however were quite
low (largest was Tau of 0.244) suggesting this effect is not
dramatic. This is of interest given the correlation of excep-
tionally high rates of radiation pneumonitis (29% grade 2,
12% grade 5) in a small series of Japanese patients treated
with a high conformality index.19 Conformality Index is
defined as prescription isodose volume divided by planning
target volume (essentially tumor volume plus set-up error)
and represents the amount of normal tissue treated to encom-
pass the target tissue in a given treatment plan. Care should
be taken to minimize the volume of normal lung treated both
to high and low doses. Our median conformality index of
1.48 is relatively low and may have been an important factor
in minimizing the risk of pneumonitis.19 Likewise, the RTOG
0236 protocol suggests conformality index should be kept
below 1.2 except in small tumors (2.5 cm axial or 1.5 cm
craniocaudal tumor volume dimension)25 where this can not
be accomplished because of minimum field size restrictions.
Most series describe a clinical pneumonitis risk of less
than 5%.4,8–10,15,16,20,22,23,28
Significant individual variations in PFT parameters
were observed, however, there was no significant change for
the population as a whole. This is consistent with a previous
study in which worsening dyspnea scores were noted at some
point after SBRT in 40% of patients.5 The authors, however,
noted a high prevalence of dyspnea at baseline (64%) and
large interindividual variability in the onset and duration of
dyspnea aggravation with no relation to timing of SBRT. In
our study, we found no correlation of PFT changes to radia-
tion dose, tumor volume, or tumor location. Likewise, there
was no difference in patient or treatment characteristics
between the patients with the largest increases and those with
the largest decreases in FEV1%. Large individual patient
fluctuations in PFT’s (which we observed in both the positive
and negative direction at nearly equal magnitude) may thus
be more related to fluctuations in the patient’s underlying
comorbid medical illness than to treatment with SBRT.
To examine the tolerability of SBRT in patients with
varying degrees of baseline pulmonary function we divided
patients into quartiles by FEV1% and DLCO. A similar
analysis was recently reported by Indiana demonstrating the
seemingly counter-intuitive result that patients with lower
FEV1 values actually had better overall survival.21 They
postulated this may be due to patients in the higher spectrum
of FEV1 being more likely to be inoperable because of
cardiac comorbidity.
We chose to divide patients by FEV1% rather than
FEV1 to minimize potential confounding effects of patient’s
height, age, and gender. Patient’s with lower FEV1% had
statistically superior survival and FEV1% above median was
as strong a predictor of overall survival (HR  3.12) as
T-stage (HR  2.83). That no patient was refused treatment
based on pulmonary function and the lowest quartile of
FEV1% (from 15 to 36% predicted) had better survival than
the group as a whole while there was no significant overall
decline in PFTs suggests that SBRT appears to be safe even
in those patients with the worst pulmonary function. Anec-
dotally, the patient with the worst baseline PFTs (FEV1 0.61
liter, FEV1% 15, DCLO 16%) was alive with no evidence of
disease at last follow-up, 29 months after treatment.
Cardiac comorbidities seem to be at least in part re-
sponsible for the shorter survival of patients with FEV1%
above median. All patients dying of cardiac disease had
FEV1% at or above median and died statistically sooner than
patients dying of other causes. In addition, there was no
difference in patients’ survival when divided into quartiles by
DLCO in the Indiana study21 or ours. DLCO has been noted
to decrease in patients with longstanding congestive heart
failure29 and may already account for some comorbidities.
Notably, in addition to having more cardiac deaths, patients
with baseline FEV1% above median also had twice as many
noncardiac deaths suggesting additional factors may contrib-
ute to survival differences. To investigate other medical
comorbidities we used the Charlson index, a validated mea-
sure of assessing a patient’s risk of dying in a given time
period based on their medical comorbidities.24 Charlson in-
dex did correlate with survival in our population, however,
was not higher in patients with FEV1% above the median,
even when using an alternative modified Charlson index
incorporating more modernly identified cardiac risk factors.
Although cardiac disease is likely an important determinant
of outcome it may not be the only critical factor in a
population with significant selection bias such as medically
inoperable patients. We plan to readdress this question with a
competing risk analysis in the future when more patients and
follow-up are available.
CONCLUSION
Our findings support the safety of SBRT in early stage
NSCLC, even for those patients with extreme pulmonary
comorbidities. No patient was denied treatment based on
pulmonary function in our population and there was no
significant decline in PFTs noted with treatment. Central
lesions were safely treated with 50 Gy in 5 fractions. Patients
even in the worst quartile of FEV1% and DLCO had survival
equivalent or better than the group as a whole.
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